Showing results (421-430 of 454) with videos related to
Sort By:
Pageof 46
Blood Advances|May 12, 2026
Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell LymphomaPierre Decazes, Cedric Rossi, Pierre Sesques, et al.Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.Oncotarget|July 27, 2016
Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter studyEmilie Reboursiere, Fabien Le Bras, Charles Herbaux, et al.Nature Medicine|September 22, 2022
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphomaEmmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, et al.Blood Advances|October 22, 2025
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registryFederico Erbella, Emmannuel Bachy, Guillaume Cartron, et al.Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.American Journal of Hematology|April 8, 2024
CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC networkSylvain Choquet, Carole Soussain, Nabih Azar, et al.Lancet (London, England)|June 7, 2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.Blood|January 12, 2017
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphomaReid W Merryman, Haesook T Kim, Pier Luigi Zinzani, et al.Blood Advances|March 3, 2025
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphomaVincent Camus, Thierry Molina, Fabienne Desmots, et al.Pageof 46